METHODS: Retrospective case-control study.
METHODS: The medical records and video recordings of patients who underwent office-based thulium laser therapy for RE between November 2018 and July 2019, and office-based blue laser therapy for RE between November 2023 and March 2024 in a tertiary referral center were reviewed. The primary outcome measures used in this study were the Voice Handicap Index-10 (VHI-10) score and disease regression based on the laryngeal examination performed before and after therapy.
RESULTS: Twenty-two patients were included in this study. They were divided into 2 subgroups, 12 patients with 22 lesions who underwent office-based thulium therapy and 10 patients with 17 lesions who underwent office-based blue laser therapy. There was no significant difference in the decrease in the mean VHI-10 score following surgery between those treated with the thulium laser vs those treated with the blue laser (10.5 ± 13.15 vs 8.2 ± 5.98, P = 0.657). Nine out of 22 lesions (40.9%) treated with thulium laser regressed completely compared to 9 out of 17 lesions (52.9%) treated with a blue laser. The difference in disease regression between the two subgroups was not statistically significant (P = 0.455).
CONCLUSIONS: Blue laser and thulium laser can be used interchangeably in-office for the treatment of RE with no significant difference in patient self-perceived improvement in voice quality and disease regression. A larger study using objective measures is warranted.
方法:回顾性病例对照研究。
方法:回顾了2018年11月至2019年7月接受基于办公室的thulium激光治疗RE的患者的病历和录像,以及2023年11月至2024年3月在三级转诊中心接受基于办公室的蓝光激光治疗RE的患者。本研究中使用的主要结局指标是语音障碍指数-10(VHI-10)评分和基于治疗前后进行的喉部检查的疾病回归。
结果:本研究纳入了22例患者。他们被分为两个小组,12例22病变患者接受了基于办公室的thu治疗,10例17病变患者接受了基于办公室的蓝色激光治疗。与使用蓝色激光治疗的患者相比,手术后平均VHI-10评分的降低没有显着差异(10.5±13.15vs8.2±5.98,P=0.657)。与用蓝色激光治疗的17个病变中的9个(52.9%)相比,用the激光治疗的22个病变中的9个(40.9%)完全消退。两个亚组之间的疾病消退差异无统计学意义(P=0.455)。
结论:Blue激光和cliium激光在治疗RE时可互换使用,患者自我感知的语音质量改善和疾病消退无显著差异。使用客观措施进行更大的研究是必要的。